Sachem Hill LLC Buys New Stake in Stryker Corporation $SYK

Sachem Hill LLC purchased a new stake in Stryker Corporation (NYSE:SYK) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 1,687 shares of the medical technology company’s stock, valued at approximately $531,000. Stryker comprises approximately 0.1% of Sachem Hill LLC’s investment portfolio, making the stock its 19th biggest position.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in SYK. Gables Capital Management Inc. acquired a new position in shares of Stryker in the 2nd quarter valued at about $25,000. Godfrey Financial Associates Inc. purchased a new stake in shares of Stryker in the fourth quarter worth about $26,000. Sankala Group LLC acquired a new stake in Stryker during the fourth quarter worth about $26,000. United Financial Planning Group LLC purchased a new position in Stryker during the third quarter valued at approximately $27,000. Finally, Atlas Capital Advisors Inc. purchased a new position in Stryker during the fourth quarter valued at approximately $27,000. 77.09% of the stock is owned by institutional investors and hedge funds.

Stryker Stock Performance

Shares of SYK stock opened at $340.20 on Thursday. The company has a current ratio of 2.16, a quick ratio of 1.33 and a debt-to-equity ratio of 0.59. Stryker Corporation has a 12-month low of $281.00 and a 12-month high of $396.86. The business’s 50 day moving average is $326.19 and its two-hundred day moving average is $332.95. The company has a market capitalization of $130.49 billion, a P/E ratio of 35.25, a P/E/G ratio of 2.11 and a beta of 0.76.

Stryker (NYSE:SYK) last posted its quarterly earnings data on Thursday, July 30th. The medical technology company reported $3.69 EPS for the quarter, beating analysts’ consensus estimates of $3.49 by $0.20. The business had revenue of $6.59 billion during the quarter, compared to analysts’ expectations of $6.58 billion. Stryker had a return on equity of 23.63% and a net margin of 14.43%.The business’s revenue was up 9.4% compared to the same quarter last year. During the same period in the previous year, the business earned $3.13 earnings per share. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. Analysts expect that Stryker Corporation will post 15.02 EPS for the current fiscal year.

Stryker Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Wednesday, September 30th will be issued a $0.88 dividend. This represents a $3.52 annualized dividend and a yield of 1.0%. The ex-dividend date of this dividend is Wednesday, September 30th. Stryker’s payout ratio is presently 36.48%.

Insiders Place Their Bets

In other Stryker news, VP Robert S. Fletcher sold 4,544 shares of the company’s stock in a transaction on Thursday, May 28th. The shares were sold at an average price of $306.87, for a total transaction of $1,394,417.28. Following the completion of the transaction, the vice president directly owned 10,582 shares in the company, valued at approximately $3,247,298.34. This represents a 30.04% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Debra King sold 826 shares of the stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $336.30, for a total transaction of $277,783.80. Following the transaction, the insider directly owned 6,210 shares in the company, valued at approximately $2,088,423. The trade was a 11.74% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 315,370 shares of company stock worth $98,463,501. Company insiders own 4.60% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on SYK shares. Wolfe Research lowered Stryker from an “outperform” rating to a “peer perform” rating in a research report on Thursday, August 13th. Leerink Partners cut their target price on shares of Stryker from $410.00 to $407.00 and set an “outperform” rating for the company in a report on Friday, June 5th. The Goldman Sachs Group reiterated a “neutral” rating and issued a $361.00 target price on shares of Stryker in a research note on Friday, May 1st. Wall Street Zen raised shares of Stryker from a “hold” rating to a “buy” rating in a report on Saturday, August 8th. Finally, Robert W. Baird set a $385.00 price target on shares of Stryker in a research report on Friday, May 1st. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have issued a Hold rating to the company’s stock. According to MarketBeat.com, Stryker presently has an average rating of “Moderate Buy” and an average target price of $386.28.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.